Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes…
Browsing: Multiple Myeloma
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
What is the Role of Maintenance Therapy and What do you do After
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Updates On The FORTE Trial: 3 Arm Study, Higher…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Smoldering Myeloma ECOG Trial: Patients With Intermediate & High…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses B-Cell Maturation Antigen (BCMA): Many Trials Using This Marker…
Katja Weisel from University Medical Center Hamburg-Eppendorf discusses the role of daratumumab in first line treatment. Background: MM patients (pts)…
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone. Background: MM…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Jakob Lindberg CEO Of Oncopeptides Discusses Melflufen Study: Lengthy Time To Next Treatment, Significant Reduction In Bone Pain, Positive Feedback…
Jakob Lindberg CEO Of Oncopeptides Discusses How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly…
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Could Be A Pivotal Study In The…
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Phase 3 Randomized Study Of Daratumumab +…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-05 This on-demand webcast examines recent clinical trial data for novel and emerging therapies,…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, More Trials & Drugs Coming In 2019. At…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, How MAIA & FORTE Trials Effect Clinicians. At…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials.…
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses How The MAIA Trial Will Effect Clinicians . At…
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses Highlights Of The MAIA Trial. At MOASC on Jan…
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, Discusses Clinical Data That Could Change…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Current…
Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses Frontline MM Treatment Patterns. At The 60th ASH Annual Meeting on Dec 1,…
Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses TOURMALINE-MM3 Study In MM. At The 60th ASH Annual Meeting on Dec 1,…
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, Discusses The Role Of Checkpoint…
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Proteasome Inhibitors In The…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study.…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses The…
Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses Thoughts On The POLLUX &…
Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses ALCYONE Trial. At The 60th…